Your browser is no longer supported. Please, upgrade your browser.
PRTA Prothena Corporation plc daily Stock Chart
Prothena Corporation plc
Index- P/E- EPS (ttm)-2.02 Insider Own0.03% Shs Outstand39.91M Perf Week2.46%
Market Cap530.47M Forward P/E- EPS next Y-1.95 Insider Trans0.00% Shs Float39.90M Perf Month18.22%
Income-80.40M PEG- EPS next Q-0.62 Inst Own97.20% Short Float3.48% Perf Quarter15.17%
Sales0.80M P/S663.09 EPS this Y50.50% Inst Trans-0.01% Short Ratio4.59 Perf Half Y-1.68%
Book/sh6.39 P/B2.02 EPS next Y4.90% ROA-18.60% Target Price13.33 Perf Year43.44%
Cash/sh8.58 P/C1.50 EPS next 5Y5.20% ROE-28.70% 52W Range6.71 - 17.63 Perf YTD-18.45%
Dividend- P/FCF- EPS past 5Y-46.40% ROI-31.50% 52W High-26.77% Beta1.86
Dividend %- Quick Ratio21.10 Sales past 5Y-56.30% Gross Margin- 52W Low92.40% ATR0.68
Employees51 Current Ratio21.10 Sales Q/Q-50.00% Oper. Margin- RSI (14)58.10 Volatility5.51% 5.96%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.80% Profit Margin- Rel Volume0.78 Prev Close12.28
ShortableYes LT Debt/Eq0.00 EarningsAug 06 AMC Payout- Avg Volume302.22K Price12.91
Recom2.60 SMA203.40% SMA5014.29% SMA20010.75% Volume235,039 Change5.09%
Jul-09-20Upgrade Oppenheimer Perform → Outperform $16
Nov-19-19Upgrade Evercore ISI In-line → Outperform $14
May-21-18Downgrade Barclays Equal Weight → Underweight $14 → $12
Apr-23-18Downgrade Jefferies Buy → Hold
Apr-05-18Reiterated Barclays Overweight $70 → $50
Nov-20-17Downgrade Wedbush Outperform → Neutral $75 → $55
Sep-29-17Reiterated BTIG Research Buy $80 → $77
Sep-15-17Initiated RBC Capital Mkts Outperform $87
Aug-17-17Initiated Evercore ISI Outperform $83
Jul-11-17Initiated Jefferies Buy
Apr-12-17Initiated Piper Jaffray Overweight $69
Apr-12-17Initiated Cantor Fitzgerald Overweight $86
Mar-02-17Initiated Instinet Buy $87
Dec-21-16Initiated SunTrust Buy $75
Nov-03-16Initiated Deutsche Bank Buy $73
Aug-04-16Reiterated Barclays Overweight $60 → $70
May-13-16Initiated Barclays Overweight $60
Feb-19-16Reiterated Wedbush Outperform $81 → $77
Jan-21-16Initiated Credit Suisse Outperform
Nov-19-15Reiterated RBC Capital Mkts Outperform $75 → $95
Aug-06-20 08:10PM  
Aug-05-20 04:05PM  
Aug-03-20 12:09PM  
Jul-30-20 04:05PM  
Jul-28-20 12:33PM  
Jul-10-20 08:34AM  
Jun-19-20 12:47PM  
May-27-20 04:05PM  
May-18-20 07:26AM  
May-06-20 07:45PM  
Apr-29-20 04:05PM  
Apr-28-20 12:33PM  
Apr-24-20 04:30PM  
Apr-22-20 09:15AM  
Apr-21-20 10:20AM  
Apr-03-20 04:05PM  
Mar-31-20 04:05PM  
Mar-13-20 11:30AM  
Mar-03-20 04:05PM  
Feb-17-20 06:31PM  
Feb-13-20 10:45AM  
Feb-12-20 05:35PM  
Feb-05-20 04:05PM  
Jan-20-20 11:21AM  
Dec-30-19 08:35AM  
Dec-11-19 03:47PM  
Dec-05-19 04:05PM  
Nov-19-19 11:03AM  
Nov-06-19 03:14PM  
Nov-05-19 06:55PM  
Oct-29-19 04:05PM  
Oct-15-19 01:49AM  
Oct-07-19 09:00AM  
Sep-20-19 01:04PM  
Sep-11-19 01:39PM  
Sep-05-19 09:31AM  
Aug-06-19 07:25PM  
Jul-30-19 04:05PM  
Jul-05-19 04:39PM  
Jul-03-19 03:26PM  
Jul-01-19 04:05PM  
Jun-06-19 09:31AM  
May-30-19 04:05PM  
May-11-19 01:28PM  
May-08-19 08:51AM  
May-07-19 06:55PM  
Apr-30-19 04:05PM  
Apr-18-19 04:05PM  
Apr-04-19 12:12PM  
Mar-26-19 04:25PM  
Mar-16-19 09:30AM  
Mar-15-19 06:48PM  
Mar-14-19 05:15PM  
Mar-12-19 11:11AM  
Mar-05-19 04:05PM  
Mar-01-19 06:29AM  
Feb-15-19 02:03PM  
Feb-14-19 05:50PM  
Feb-07-19 10:31AM  
Feb-04-19 04:05PM  
Jan-30-19 08:15AM  
Dec-20-18 06:04AM  
Dec-10-18 08:38AM  
Dec-06-18 09:30AM  
Nov-08-18 09:59AM  
Nov-06-18 07:05PM  
Oct-30-18 04:05PM  
Oct-16-18 09:10AM  
Oct-09-18 08:32AM  
Oct-01-18 10:10AM  
Sep-13-18 06:17PM  
Sep-06-18 08:21PM  
Sep-02-18 09:12AM  
Aug-31-18 08:24PM  
Aug-28-18 08:15PM  
Aug-21-18 05:08PM  
Aug-20-18 08:00AM  
Aug-09-18 02:39PM  
Aug-08-18 08:18AM  
Aug-07-18 07:35PM  
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; A, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.